Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.43 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.43 |
| ▸ | CATSPER1 | Q8NEC5 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL427022 | 0.83 | CA12 (0.49) | CA12CA1CA2CA9TBXA2R | |
| SCHEMBL8936017 | 0.82 | CATSPER1 (0.39) | CA12CA1CA2CA9TBXA2R | |
| SCHEMBL10002291 | 0.82 | CA12 (0.56) | CA12CA1CA2CA9TBXA2R | |
| SCHEMBL8936076 | 0.78 | GLA (0.44) | CA12CA1CA2CA9MAPT | |
| SCHEMBL10002281 | 0.76 | CA12 (0.53) | CA12CA1CA2CA9TBXA2R | |
| SCHEMBL8785232 | 0.75 | CA12 (0.37) | CA12CA1CA2CA9TBXA2R | |
| SCHEMBL2079547 | 0.74 | GLA (0.58) | CA12CA1CA2CA9MAPT | |
| SCHEMBL11148691 | 0.74 | ABCB1 (0.49) | CA12CA1CA2CA9TBXA2R | |
| SCHEMBL27463748 | 0.73 | ABCB1 (0.45) | CA12CA1CA2CA9ABCB1 | |
| SCHEMBL8259009 | 0.72 | CA12 (0.48) | CA12CA1CA2CA9ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011076019-A1 | MIXED COMPOUND MEDICAMENT OF NATURAL MEDICINE COMPONENT AND NO DONATOR AND USE THEREOF | 奇复康药物研发(苏州)有限公司 (CN) | 2011-06-30 | — | — | WO | claimed |
| WO-2010035047-A1 | BINARY COMPOSITIONS COMPRISING AN NO-DONOR AND AN A-SMASE INHIBITOR FOR THE TREATMENT OF RESPIRATORY DISEASES | PHARMAPATENTS GLOBAL LTD. (GB) | 2010-04-01 | — | — | WO | claimed |
| US-20090203050-A1 | MOLECULAR SIGNALING PATHWAYS TRIGGERED BY RITUXIMAB: PROGNOSTIC, DIAGNOSTIC, AND THERAPEUTIC USES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-08-13 | — | — | US | claimed |
| US-20080311039-A1 | Therapeutic and Prognostic Factor Yy1 in Human Cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-12-18 | — | — | US | claimed |
| US-20070172847-A1 | MOLECULAR SIGNALING PATHWAYS TRIGGERED BY RITUXIMAB: PROGNOSTIC, DIAGNOSTIC, AND THERAPEUTIC USES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-07-26 | — | — | US | claimed |
| WO-2007011372-A2 | THERAPEUTIC AND PROGNOSTIC FACTOR YY1 IN HUMAN CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-25 | — | — | WO | claimed |
| US-20240415795-A1 | TOPICAL FORMULATIONS OF NITROGLYCERIN | PERMEATUS, INC. | 2024-12-19 | — | — | US | disclosed |
| US-12070440-B2 | Topical formulations of nitroglycerin | PERMEATUS, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| WO-2024006305-A1 | TOPICAL FORMULATIONS OF NITROGLYCERIN | PERMEATUS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230414551-A1 | TOPICAL FORMULATIONS OF NITROGLYCERIN | PERMEATUS, INC. | 2023-12-28 | — | — | US | disclosed |
| EP-2376461-B1 | NITRIC OXIDE FUROXAN DERIVATIVE COMPOUNDS ENDOWED WITH ANTITUMORAL ACTIVITY | HUMANITAS MIRASOLE SPA (IT) | 2015-03-11 | — | — | EP | disclosed |
| US-8946271-B2 | Water soluble furoxan derivatives having antitumor activity | HUMANITAS MIRASOLE S.P.A. (IT) | 2015-02-03 | — | — | US | disclosed |
| US-8592464-B2 | Nitric oxide furoxan derivative compounds endowed with antitumoral activity | HUMANITAS MIRASOLE S.P.A. (IT) | 2013-11-26 | — | — | US | disclosed |
| EP-1143956-A3 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANORECTAL DISORDERS | Cellegy Pharmaceuticals, Inc (US) | 2001-12-12 | — | — | EP | disclosed |
| EP-1143956-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANORECTAL DISORDERS | Cellegy Pharmaceuticals, Inc (US) | 2001-10-17 | — | — | EP | disclosed |
| US-20010012856-A1 | Compositions and methods for the treatment of anorectal disorders | CELLEGY PHARMACEUTICALS, INC. | 2001-08-09 | — | — | US | disclosed |
| WO-2000035434-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANORECTAL DISORDERS | CELLEGY PHARMACEUTICALS, INC. (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-1999055317-A2 | TREATMENT OF ADVANCED DECOMPENSATED HEART FAILURE WITH NITRIC OXIDE DONORS | THE JOHNS HOPKINS UNIVERSITY (US) | 1999-11-04 | — | — | WO | disclosed |
| CN-1043140-C | Chlorins, isobacteriochlorins, bacteriochlorins, and methods of making the compounds described herein from the beta, beta'-unsubstituted tetrapyrrole macrocycle | HOECHST AG (DE) | 1999-04-28 | — | — | CN | disclosed |
| CN-1119013-A | Hydroxymethyl furazan carboxylic acid derivatives and their use in the treatment of cardiovascular disease | CASSELLA FARBWERKE MAINKUR AG (DE) | 1996-03-20 | — | — | CN | disclosed |